What Astragalus Is and Why It's Studied
Astragalus membranaceus is a root used for centuries in traditional Chinese medicine and now studied in laboratories worldwide for its chemical constituents and biological activity [PMID: 25087616]. The dried root, sometimes labeled Astragali Radix or by its Chinese name Huangqi, contains more than 100 identified compounds, including polysaccharides, saponins, flavonoids, and amino acids [PMID: 25087616]. Contemporary research has organized around three main compound classes—Astragalus polysaccharides (APS), astragaloside saponins, and flavonoid compounds—each studied separately for distinct biological effects [PMID: 32265719] [PMID: 26916911].
This chemical complexity matters for interpreting the evidence base. A study using a purified polysaccharide fraction administered by injection to mice does not speak to the same substance as a crude root extract taken orally by a person. Reviewers of the traditional literature note that specifications for species, plant part, extraction method, and marker-compound concentration vary considerably across the studies that get grouped together under the single name "Astragalus" [PMID: 25087616]. This review inventories what has actually been tested, in what form, in what organism, and toward what outcome—and separates that evidence from the broader traditional and commercial narrative around the herb.
The Core Mechanistic Claim: Immune Signaling
The most consistently studied activity of Astragalus involves its polysaccharide fraction and immune cell signaling. Laboratory work has examined how APS interacts with immune receptors at the cellular level. One frequently cited study found that Astragalus polysaccharides activated mouse B cells and macrophages, but not T cells, based on measures of proliferation and cytokine production in vitro [PMID: 15249203]. That same study used fluorescence labeling to show that APS bound selectively to B cells, macrophages, and a human tumor cell line (THP-1) in laboratory culture, and that this binding could be blocked by bacterial lipopolysaccharide, suggesting the polysaccharide interacts with pattern-recognition pathways shared with bacterial cell-wall components [PMID: 15249203].
Follow-up mechanistic work using genetically altered mice further probed this pathway. Research using macrophage cell lines and tumor-bearing mice found that Astragalus polysaccharide administration increased nitric oxide and inflammatory cytokines (TNF-α, IL-1β, IL-6), and that this effect depended on an intact Toll-like receptor 4 (TLR4) and MyD88 signaling cascade—mice lacking functional TLR4 or MyD88 did not show the same response [PMID: 28303957]. This is a mechanistic, animal-and-cell-based finding. It identifies a plausible biological pathway; it does not establish that oral Astragalus supplementation produces a measurable immune change in humans.
Broader reviews of Astragalus polysaccharide pharmacology summarize a wider set of claimed immune actions drawn largely from animal and in vitro data: increases in immune organ weight indices (spleen, thymus), stimulation of immune cell proliferation, altered cytokine release, and effects on immunoglobulin secretion [PMID: 32265719]. A separate narrative review focused specifically on the immunomodulatory literature reports that Astragalus polysaccharide has been studied for effects on bone marrow, thymus, lymph nodes, spleen, and mucosal tissue, and for activity across macrophages, natural killer cells, dendritic cells, T lymphocytes, B lymphocytes, and microglia in various experimental systems [PMID: 35713852]. The same review is explicit that further high-quality studies are needed to corroborate clinical efficacy, an important qualifier given how much of the underlying data comes from animal models rather than controlled human trials [PMID: 35713852].
Animal Tumor Models: A Distinct and Separate Body of Work
A substantial share of the Astragalus polysaccharide literature involves rodent cancer models, and this evidence needs to be kept analytically distinct from immune-function research in healthy subjects. In one study, researchers implanted H22 hepatocarcinoma tumor cells into mice and then administered Astragalus membranaceus polysaccharide at two doses (100 and 400 mg/kg) [PMID: 24060282]. The treated mice showed slower solid tumor growth, along with improvements in body weight, spleen and thymus index, and macrophage phagocytic function compared to untreated tumor-bearing mice, alongside increased IL-2, IL-12, and TNF-α and decreased IL-10 in serum [PMID: 24060282]. The authors describe this as evidence that the polysaccharide's antitumor activity in this mouse model operates at least partly through modulating the host immune response [PMID: 24060282].
A separate line of work using 4T1 breast cancer cells found that Astragalus polysaccharide had no direct toxic effect on the cancer cells themselves in a dish, but that polysaccharide-treated macrophages could inhibit tumor cell growth indirectly, apparently by triggering cell cycle arrest and apoptosis through a mitochondrial pathway [PMID: 31669273]. In mice, this same research group reported improved thymus and spleen indices, enhanced spleen lymphocyte proliferation, and increased macrophage phagocytosis after polysaccharide treatment, and found that combining the polysaccharide with the chemotherapy drug 5-fluorouracil eased some of the immune suppression normally caused by that drug in the animal model [PMID: 31669273].
These are legitimate scientific findings, but they describe implanted tumors in inbred laboratory mice given specific polysaccharide doses by specific routes of administration. They cannot be extrapolated to describe what happens when a person consumes an oral Astragalus product. No dose-equivalence, route-of-administration equivalence, or species-translation has been established by this literature, and none of these studies were designed to test a commercial supplement.
Human-Facing Literature: Adjuvant Use Alongside Cancer Treatment
The clinical evidence most directly relevant to humans comes from the oncology-adjuvant literature, which is also the area requiring the most careful interpretation. A review of Chinese herbal medicines used alongside chemotherapy or radiotherapy discusses Astragalus as one of several herbs (alongside turmeric, ginseng, and specific proprietary formulations) studied in this context [PMID: 21248427]. The review states that preclinical and clinical studies have examined whether such herbs can improve immune system function, increase sensitivity to chemo- and radiotherapy, and lessen treatment-related damage, and that some clinical work has looked at effects on cancer-related fatigue, pain, respiratory infections, and gastrointestinal side effects during cancer treatment [PMID: 21248427]. This is a review summarizing a mixed and heterogeneous literature; it is not a report of a single controlled trial isolating Astragalus's effect, and it concerns people already undergoing active cancer treatment under medical supervision—a context entirely distinct from general wellness use.
A separate review focused on Astragalus and gastrointestinal cancer describes similar territory: it reports that Astragalus-based treatments have been investigated for reducing toxicity from concurrently administered immunosuppressant and chemotherapy drugs, and it discusses proposed mechanisms by which the herb's saponins, polysaccharides, and flavonoids might influence immune signaling and cancer-related pathways [PMID: 26916911]. The review explicitly frames this as a synthesis of experimental and clinical studies aimed at informing future drug development, rather than as an endorsement of Astragalus as a standalone treatment [PMID: 26916911].
It is worth being precise about what this body of literature does and does not represent. These are reviews of herbal medicine used as a supplementary measure in medically supervised cancer care, in populations undergoing chemotherapy or radiotherapy—not evidence about Astragalus taken independently by generally healthy adults for immune support. The trials referenced within these reviews vary widely in design, herbal formulation (many are multi-herb combinations rather than Astragalus alone), dose, and outcome measures, which limits how much can be generalized even within the oncology-adjuvant context.
Broader Immunomodulatory Reviews
Several review articles attempt to synthesize the full breadth of Astragalus immune research across animal, cell, and limited clinical data. One review covering Astragali Radix describes it as having roles in supporting immune organ development, mucosal immune function, and both innate immunity (increased phagocytic activity) and acquired immunity (maturation of immune cells, antibody expression), based on a synthesis of preclinical and clinical literature [PMID: 32330511]. Notably, this review's own framing acknowledges that Astragalus "could be a breakthrough point" for future research rather than describing an established clinical benefit [PMID: 32330511]—language that signals a research agenda, not a confirmed outcome.
An older comparative review examining several traditional Chinese herbs, including Astragalus, alongside Aloe vera, Panax ginseng, and others, found that each plant appeared to have at least one compound that selectively affected immune cells in laboratory testing, and noted that some of these herbs also showed direct antimicrobial activity against pathogens [PMID: 15180575]. This review is more than two decades old and focuses primarily on identifying bioactive compounds and proposing them as candidates for future pharmaceutical development, rather than reporting confirmed human outcomes [PMID: 15180575].
A more recent review specifically addressing Astragalus polysaccharide's immunomodulatory profile lists a range of conditions for which the compound has been proposed as a candidate therapy, including cancer, infection, type 1 diabetes, asthma, and autoimmune disease, and states that its anticancer effect is the most prominent theme in the literature [PMID: 35713852]. Critically, this same review closes by stating that further high-quality studies are needed to corroborate clinical efficacy [PMID: 35713852]—an acknowledgment that the disease-application claims populating this literature remain hypotheses generated from preclinical work rather than findings confirmed in controlled human trials.
The Anti-Aging Angle: A Narrower and More Speculative Thread
A distinct strand of Astragalus research concerns aging biology, most notably through a proprietary extract called TA-65, studied for potential effects on telomerase activity. A review on Astragalus and aging reports that this specific extract "was associated with a significant age-reversal effect in the immune system," citing experimental and clinical studies [PMID: 29344421]. The same review describes broader pharmacological findings attributed to Astragalus membranaceus extract components, including antioxidant, anti-inflammatory, immunoregulatory, hypolipidemic, and antihyperglycemic effects, again drawing on a mix of experimental and clinical sources [PMID: 29344421].
This aging-focused work deserves particular caution for readers. TA-65 is a specific, proprietary, standardized extract—not equivalent to raw Astragalus root, a generic polysaccharide extract, or any unspecified "Astragalus" ingredient found in a supplement. Findings attributed to this single proprietary preparation cannot be assumed to apply to other Astragalus-derived products with different extraction methods, standardization, or dosing. The review itself is a narrative synthesis rather than a single controlled trial, and it draws together disparate experimental systems—cell culture, animal models, and limited clinical observations—under a broad "anti-aging" framing that outpaces what any individual study demonstrates.
What the Evidence Does Not Show
Several gaps and limitations recur across this literature and deserve explicit statement.
- Controlled human trials isolating Astragalus alone are scarce. Much of the clinical-sounding literature discussed above involves Astragalus as one component of multi-herb formulations, administered alongside conventional cancer treatment, or reviewed narratively rather than tested against placebo in a randomized trial designed to isolate its independent effect [PMID: 21248427] [PMID: 26916911].
- Most mechanistic and immune-signaling data come from animal or cell-culture systems. Findings involving mouse B cells, macrophages, TLR4-knockout mice, and cultured tumor cell lines describe biological plausibility, not demonstrated human outcomes [PMID: 15249203] [PMID: 28303957] [PMID: 31669273] [PMID: 24060282].
- Tumor-model research in mice cannot be read as evidence of anticancer benefit in humans. Implanted-tumor studies using injected or orally dosed polysaccharide fractions in inbred mouse strains are a distinct evidentiary category from human clinical outcomes, and none of the cited animal studies were designed to establish a treatment claim in people [PMID: 24060282] [PMID: 31669273].
- Formulation and compound identity vary widely across studies. "Astragalus" in this literature ranges from crude dried root to purified polysaccharide fractions to a single proprietary extract (TA-65), and these are not interchangeable substances with equivalent evidence bases [PMID: 25087616] [PMID: 29344421].
- Reviews synthesizing this field consistently call for more rigorous clinical research. Authors of recent reviews explicitly state that further high-quality studies are needed before clinical efficacy claims can be corroborated [PMID: 35713852], and describe existing findings as providing a theoretical basis for future research rather than settled clinical conclusions [PMID: 32265719].
- None of this literature supports diagnosing, treating, curing, or preventing any disease. Disease-related associations in these papers—cancer, diabetes, autoimmune conditions—are framed by the source authors themselves as research directions or preclinical hypotheses, not as demonstrated clinical treatments.
Readers should also note that oncology-adjuvant research involving Astragalus concerns people undergoing active, medically supervised cancer treatment—a context with no bearing on general wellness use by healthy adults, and one that underscores why any use of Astragalus alongside a diagnosed condition or prescribed medication warrants direct discussion with a qualified clinician rather than inference from this literature.
Reading This Evidence Base as a Whole
Taken together, the Astragalus literature shows a consistent mechanistic story at the cell and animal level: polysaccharide fractions appear to interact with pattern-recognition receptors on immune cells, particularly through TLR4-linked signaling, and this interaction is associated with changes in cytokine production and immune organ measures in mice [PMID: 15249203] [PMID: 28303957]. This mechanistic consistency across multiple independent research groups is a genuine feature of the literature. What it is not is proof that any specific oral Astragalus product produces a measurable immune or health effect in humans. The gap between "a purified polysaccharide activates macrophages in a petri dish" and "a supplement supports immune function in a person" spans differences in compound purity, dose, route of administration, species, and study design that this literature has not yet bridged with controlled human trials.
Selected Sources
- PMID: 25087616 — Review of botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus
- PMID: 32265719 — Review of the pharmacological action of Astragalus polysaccharide
- PMID: 26916911 — Astragalus and protection against inflammation and gastrointestinal cancers (review)
- PMID: 15249203 — Immune receptor study of Astragalus polysaccharides in mouse cells
- PMID: 21248427 — Chinese herbal medicines as adjuvant treatment during chemo/radiotherapy (review)
- PMID: 29344421 — Anti-aging implications of Astragalus membranaceus (review)
- PMID: 32330511 — Astragali Radix as an edible immunomodulatory herbal medicine (review)
- PMID: 35713852 — Astragalus polysaccharide immunomodulatory effect (review)
- PMID: 31669273 — Anti-tumor bioactivity of Astragalus polysaccharides via immunomodulation (mouse/cell study)
- PMID: 28303957 — Astragalus polysaccharides and TLR4-mediated MyD88 signaling (in vitro/in vivo)
- PMID: 15180575 — Immunomodulatory and antimicrobial effects of traditional Chinese medicinal herbs (review)
- PMID: 24060282 — Antitumor and immunomodulatory activity of Astragalus polysaccharides in tumor-bearing mice
Editorial Note
This article was compiled from peer-reviewed review articles and primary laboratory/animal studies identified through PubMed. It is intended to describe the current state of published research on Astragalus membranaceus, including its mechanistic, animal, and limited clinical literature, and to distinguish between these categories of evidence. It does not evaluate or endorse any specific commercial product, and it does not substitute for individualized medical advice. High-risk contexts discussed in the source literature—cancer treatment, autoimmune conditions, diabetes—are noted here strictly as research topics found in the cited papers, not as recommendations.
This article is for educational purposes only and has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before making decisions about supplements, especially if you are pregnant, nursing, managing a medical condition, or taking medication.
